Company Overview and News

 
NZ shares fall as Meridian faces declining hydro storage

2018-10-16 nzherald.co.nz
New Zealand shares fell for a second day with Meridian Energy lower as the power company confronts dry conditions, and exporters Comvita and Fisher & Paykel Healthcare faced a stronger kiwi dollar.
RHCGF SPKKY EBOSY NZTCY SPK NZTCF RYM EBO SKT GNE AOTUF EBOSF SYKWF PPSHY RYHTY VTHPF SKKTY GNE MEZ GEL EBO

 
NZ shares fall as A2 Milk extends decline

2018-09-27 nzherald.co.nz
New Zealand shares fell as A2 Milk Co extended its decline since its chief executive sold down her holding. Rising bond yields also dimmed the lustre of property stocks.
AIA FBU FCREY SPKKY EBOSY NZTCY SPK NZTCF ACKDF FRCEF EBO AUKNY KWIPF AOTUF EBOSF SKC AIA FBU THL VTHPF SKLUY SKL MEZ EBO

 
NZ shares up; Pushpay, SkyCity gain

2018-08-09 nzherald.co.nz
New Zealand shares gained as the dollar sank following the official cash rate update, with Pushpay Holdings recovering from recent selling and SkyCity Entertainment Group continuing to gain.
KTHDY FBU FCREY NZR FRCEF FTRRF KMD SKC PPSHY FBU VTHPF GTK KMD

 
NZ shares mixed in light trading, Sky TV and Stride rise while A2, Westpac drop

2018-07-04 nzherald.co.nz
New Zealand shares were mixed in light trading, with Sky Network Television and Stride Property leading gains while A2 Milk Co and Westpac Banking Corp fell.
AIA WBC WEBNF WBK ACKDF AUKNY SKT SYKWF AIA WBC VTHPF SKKTY GTK SML

19
Brave or foolish? Healthscope keeps the doors closed

2018-05-22 theage.com.au
The Healthscope board has made a brave response to the twin overtures from private equity, choosing to give them the cold shoulder rather than engage.
BAMGF VTHPF BAMKF BAM

19
Brave or foolish? Healthscope keeps the doors closed

2018-05-22 smh.com.au
The Healthscope board has made a brave response to the twin overtures from private equity, choosing to give them the cold shoulder rather than engage.
BAMGF VTHPF BAMKF BAM

16
Shares rise, led by A2 and Synlait

2018-05-17 nzherald.co.nz
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.
BGR WBC SPKKY NZTCY SPK NZTCF WEBNF WBK SKT SYKWF WBC PPSHY VTHPF SKKTY SML

20
A2 tumbles, dragging down stock index

2018-05-16 nzherald.co.nz
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.
FBU RHCGF FCREY SPKKY NZTCY SPK NZTCF RYM FRCEF SKT SYKWF FBU RYHTY VTHPF SNZ SKKTY SML

10
Shares keep falling amid global sell-off

2018-03-26 nzherald.co.nz
New Zealand's S&P/NZX 50 Index fell about 1 per cent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
AIR ANZFY AIZ SKT SYKWF NZSTY ANZLY VTHPF NZSTF SKKTY ANZFF GTK SML AUG

10
MARKET CLOSE: NZ shares join global sell-off

2018-03-26 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index fell about 1 percent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
AIR ANZFY AIZ SKT SYKWF NZSTY ANZLY VTHPF NZSTF SKKTY ANZFF GTK SML AUG

25
MARKET CLOSE: NZ shares rise on Summerset upgrade; Synlait gains while Argosy, Strike shed dividends

2018-03-13 nbr.co.nz
New Zealand shares rose, bucking a selloff in most stock markets across Asia, as an analyst upgrade for Summerset Group pushed the retirement village operator to a record high. Synlait Milk gained, while Stride Property and Argosy Property fell after shedding dividend rights.
AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ SKT SYKWF SKC PPSHY VTHPF SKKTY SML AIA FBU SPKKY NZTCY SPK FRCEF AIA FBU ANZLY ANZFF MEZ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...